Lecalcif (Colecalciferol)

Colecalciferol is converted first in the liver to 25‑hydroxyvitamin D and then in the kidney to the active hormone 1,25‑dihydroxyvitamin D. This active hormone binds to vitamin D receptors in intestinal cells, stimulating the production of calcium‑binding proteins that increase calcium and phosphate absorption from the gut, thereby supporting bone formation.

The appropriate dose of Lecalcif is determined by a qualified healthcare professional based on the individual’s serum vitamin D level, age, weight, underlying conditions, and concurrent medications. Patients should follow the prescriber’s instructions and not self‑adjust the dosage.

Safety data for colecalciferol in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any unknown risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To order Lecalcif, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lecalcif provides colecalciferol, the same active ingredient found in most vitamin D3 supplements. Differences among products may relate to dosage strength, formulation (tablet, capsule, liquid), and regulatory status. Clinicians choose a product based on the patient’s dosing needs, absorption considerations, and local availability.

Lecalcif should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat, and direct sunlight to maintain potency throughout its shelf life.

Lecalcif is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet or capsule should be swallowed whole with a glass of water. Patients should follow the specific administration instructions provided by their healthcare provider.

The most serious risks involve excessive calcium levels, known as hypercalcaemia, which can cause cardiac arrhythmias, kidney stones, or renal impairment. Rarely, severe allergic reactions such as anaphylaxis may occur. Patients should report symptoms like persistent nausea, vomiting, muscle weakness, or unusual fatigue to their doctor promptly.

Individuals with known hypersensitivity to colecalciferol or any excipients in the formulation should avoid Lecalcif. Patients with uncontrolled hypercalcaemia, severe renal disease, or certain granulomatous disorders (e.g., sarcoidosis) should use it only under close medical supervision.